Literature DB >> 22366902

Photodynamic therapy for symptomatic subretinal fluid related to choroidal nevus.

Jose García-Arumí1, Luis Amselem, Kaan Gunduz, Jose Badal, Alfredo Adan, Miguel A Zapata, Xavier Valldeperas, Frederic Huste, Borja Corcóstegui.   

Abstract

PURPOSE: The purpose of this article is to evaluate the role of photodynamic therapy (PDT) for symptomatic choroidal nevus with subretinal fluid (SRF) extending to the fovea.
METHODS: Retrospective review of the medical records of all patients who underwent PDT for a symptomatic choroidal nevus with SRF.
RESULTS: Seventeen patients were included in the study. The mean initial visual acuity was 20/80 (range, counting fingers to 20/20). The mean initial tumor thickness was 1.23 mm (range, 0.66-1.93 mm). All tumors presented at least 2 risk factors for growing (including orange pigment, symptoms, peripapillary location, SRF, and thickness >2 mm). The mean number of PDT sessions was 1.41 (range, 1-3). The mean final visual acuity improved to 20/60 (range, counting fingers to 20/20). Subretinal fluid was reduced in all eyes (100%) and had completely disappeared in 9 eyes (53%) after PDT. Of 9 cases with complete resolution of the SRF, 2 patients (22%) presented recurrence. The mean final tumor thickness increased to 1.24 mm (range, 0.66-2.01 mm) at a mean follow-up of 22.47 months (range, 6-60 months). Tumor thickness increased in 3 eyes (18%) and remained unchanged in 13 eyes (76%), and 1 lesion (6%) shrank down to a flat chorioretinal scar.
CONCLUSION: Photodynamic therapy is a good treatment option to reduce SRF in symptomatic choroidal nevus with serous macular detachment. Further growth into melanoma was observed in 18% of cases. Thus, PDT may not allow a good local tumor control. Longer follow-up is required to determine its value in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366902     DOI: 10.1097/IAE.0b013e318232c366

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  3 in total

1.  Selective retina therapy for subretinal fluid associated with choroidal nevus.

Authors:  Manabu Yamamoto; Yoko Miura; Akika Kyo; Kumiko Hirayama; Takeya Kohno; Dirk Theisen-Kunde; Ralf Brinkmann; Shigeru Honda
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-23

2.  Treatment of vascular activity secondary to atypical choroidal nevus using intravitreal bevacizumab.

Authors:  Milena L Cavalcante; Victor M Villegas; Aaron S Gold; Ludimila L Cavalcante; Marcela Lonngi; Nisha V Shah; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2014-07-22

3.  Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.

Authors:  Junwon Lee; Hee Jung Kwon; Min Kim; Christopher Seungkyu Lee; Sung Chul Lee
Journal:  BMC Ophthalmol       Date:  2019-05-03       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.